CAVD — Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD
Citation(s)
An Open-label, Randomized Study of Inhibitory Effect of Evogliptin, the Dipeptidyl Peptidase-4 Inhibitor, on the Progression of Aortic Valve Calcification in Patients With Type 2 Diabetes Mellitus and Mild-to-moderate Aortic Stenosis